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e under theAbstract Background: The aim of this study is to compare Tuberculin Skin Test
(TST) result and interferon gamma response to human PPD (purified protein deriva-
tive), in scar positive and scar negative BCG-vaccinated children.
Methods: Between August 2007 and May 2008 a total of 236 children aged 1–
168 months (mean 21 months) admitted toMofidChildrens Hospital, Tehran, Iran,were
enrolled in a cross-sectional study. Each patientwas examined for BCG vaccine scar and
tested with TST and human PPD-based Interferon Gamma Release Assay (IGRA).
Results: Two hundred and twenty one cases out of 236 (44% female, 1–168 months,
mean age 21 months) were scar positive of whom 95% TST result was negative. Human
PPD-based IGRAwas positive in 110 (49.8%), negative in 85 (38.4%) and indeterminate in
26 (11.8%) of scar positive patients.
Fifteen children (40% female, 1–156 months; mean age 42 months) were scar nega-
tive. All the scar negative cases were TST negative. Human PPD-based IGRA was positive
in10 (66.7%),negative in4 (26.7%)and indeterminate in1 (6.7%)of scarnegativepatients.
Conclusions: Immune responsiveness to human PPD antigens in scar positive and neg-
ative children may not correspond with results of the Tuberculin Skin Test.
ª 2013 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/3
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Tuberculosis (TB) is still one of the most important
health problems worldwide with an estimatedabia. Published by Elsevier Ltd.
creativecommons.org/licenses/by-nc-nd/4.0/).
46 S. Sayyahfar et al.prevalence of 12 million (range, 10 million–13 mil-
lion) cases in 2011 [1]. Since 1928 the BCG vaccine
has been used against Mycobacterium tuberculosis
(MTB) [2].
According to the World Health Organization
(WHO) guidelines, a single BCG vaccine should be
administered in countries with a high prevalence
of active TB disease and now it is mandated in
about 64 countries and administered in at least
167 countries [3,4].
Generally, the benefit of the BCG vaccine is seen
in the first 5 years of life, but its efficacy might
persist for 50–60 years, suggesting that a single
dose of an effective BCG vaccine could have a long
duration of protection [5].
Currently, it is the only vaccine which causes a
characteristic local reaction [6]. A scar occurs in
47.2–100% of cases up to 12 weeks after the BCG
vaccination, but may not occur at all in about
10% of infants [6].
The presence or absence of the BCG scar is often
used as an indicator of immunization against MTB,
and some pediatricians recommend revaccination
for Tuberculin Skin Test (TST) negative-scar nega-
tive children, but some studies using leukocyte
migration inhibition test showed that the absence
of a scar may not mean that the child is not immu-
nized [2]. They showed that despite scar failure,
the majority of cases could elicit a positive
in vitro cellular response [2].
Currently, there is no clear guideline for infants
who have scar failure. Also, as far as this study is
concerned, there is no documentation for using
TST by some pediatricians as a good predictor of
determining scar negative cases who might need
revaccination.
The question still exists if the presence of a BCG
vaccine scar corresponds to immunity against MTB
and if revaccination is necessary for infants who
have scar failure and a negative TST.
New advances in immunology have led to a new
in vitro test for diagnosing MTB infection named
Interferon Gamma Release Assay (IGRA). The main-
stay of this test is releasing interferon gamma from
T-lymphocytes exposed to mycobacterium antigens
[7–9]. Commercially available IGRAs have evolved
rapidly over the past decade and have used different
antigens. This test was used in this study to indicate
immune responsiveness to human purified protein
derivative (PPD) antigens in scar negative children,
as opposed to its conventional role to diagnose la-
tent tuberculosis infection (LTBI) or TB disease. As
far as this research is concerned, IGRA has not been
studied yet for evaluating immune responsiveness to
human PPD antigens in BCG scar negative cases.The aim of this study is to compare the inter-
feron gamma response to human PPD and TST re-
sult in scar negative and positive children.
2. Materials and methods
2.1. Study design and population
This cross-sectional study was conducted between
August 2007 and May 2008 at Mofid Childrens Hos-
pital, Tehran, Iran, after receiving approval from
the ethics review committee of the Pediatric Infec-
tions Research Center (PIRC).
Patients between 1 month and 14 years old
admitted to Mofid Childrens Hospital that had re-
ceived the BCG vaccine at birth and met the inclu-
sion criteria were enrolled in this study in a
sequential manner. All cases had an infectious
illness.
Informed consent was taken from their parents
before enrollment. The inclusion and exclusion cri-
teria are depicted in Table 1. Each vaccinated pa-
tient was examined for the BCG vaccine scar by a
pediatrician and then tested with both TST and hu-
man PPD-based IGRA.
2.2. Blood collection procedures
Before performing TST, 4 mL of venous blood was
collected in a sodium heparinized tube and trans-
ferred to the laboratory where four tubes for every
patient were prepared containing 150 lg (3 drops)
normal saline (negative control), phytohemaggluti-
nin (a mitogen used as a positive control), human
PPD (from MTB), and avian PPD (from Mycobacte-
rium avium) respectively; 1 mL heparinized whole
blood was added to each tube within six hours of
collection.
Aliquots of heparinized whole blood were incu-
bated with the test antigens at 37 C and in a
humidified atmosphere for 16–24 h. The tubes
were centrifuged and plasma supernatants were
collected, frozen and stored at 70 C. Enzyme-
linked immunosorbent assay (ELISA) test was per-
formed within three months of blood collection
to determine the level of interferon-gamma (IFN-
c) produced in each tube.
2.3. Interferon gamma assays
IGRA was performed according to the manufac-
turers recommendations (R&D, America). A mito-
gen and saline solution were used as positive and
negative controls, respectively. The amount of
INFc produced in response to the human PPD in ex-
Table 1 Inclusion and exclusion criteria for participant selection.
Inclusion criteria
1. BCG vaccinated at birth
2. Child aged between 1 month and 14 years
3. Admitted in the pediatric ward
4. Parent willing to provide informed consent
Exclusion criteria
1. congenital or acquired immune deficiency disorders
2. history of allergy to PPD
3. history of active tuberculosis disease or close contact to documented tuberculosis case
4. Unstable cardiopulmonary condition
5. malignancy
Comparison of Tuberculin Skin Test result and interferon gamma 47cess of the saline control (human PPD–negative
control) was calculated, as was the amount of
INF-c produced in excess of saline control by the
avian PPD (avian PPD  negative control) and also
in excess of mitogen (positive control  negative
control). A positive test result indicating immune
responsiveness to human PPD antigens was defined
by the following two criteria:
1. [(human PPD  negative control)/(positive con-
trol  negative control)P 0.15] and
2. [(human PPD  negative control)  (avian
PPD  negative control)/(human PPD  negative
control)P 0.1]
These two criteria are summarized as below:
human PPD negative control
positive control negative controlP 0:15
and
human PPD avian PPD
human PPD negative controlP 0:1
An IGRA result indicating reactivity to M. avium
complex was defined by the following two criteria:
1. [(avian PPD  negative control)/(positive con-
trol  negative control)]P 0.2 and
2. [(human PPD  negative control)  (avian
PPD  negative control)/(human PPD  negative
control) < 0.1]
These two criteria are summarized as below:
avian PPD negative control
positive control negative controlP 0:2
and
human PPD avian PPD
human PPD negative control < 0:1
The IGRA was considered to be indeterminate if
the positive control minus negative control result
was less than 0.5 IU. All other IGRA result profiles
were considered negative.2.4. Tuberculin Skin Test
Purified protein derivative 0.1 m (5 IU) (manufac-
tured by Razi Institute of Iran) was injected intrader-
mally at the junction of 1/3 proximal to 2/3 distal of
the volar side of the forearm. The induration at the
injection site was measured by a pediatrician and re-
corded in millimeters 48–72 h after the injection.
The interpretation of the results (i.e., positive or
negative TST) was performed by the pediatrician
for each case according to the recommendation of
the American Academy of Pediatrics (AAP) [10].
2.5. Statistical analysis
Quantitative data were summarized as median and
minimum–maximum and categorical data as raw
numbers and percentages. To compare frequency
of positive results between the two study groups,
chi square and Fisher exact tests were used.
P-values less than 0.05 were considered as sta-
tistical significant. Agreement (actual agreement)
was calculated by dividing concordant results
(those cases with similar results of TST and IGRA
tests) by total of cases. The Kappa statistics were
calculated to test the difference of actual agree-
ment to chance agreement and interpreted accord-
ing to Landis and Koch suggestions.
Values of <0.4, 0.4–0.75 and >0.75 were consis-
tent with poor, good and excellent concordance,
respectively.3. Results
Out of 236 patients enrolled in this study, 103
(46.6%) were female. The mean age of the patients
was 21 months (from1 month to 14 years). The num-
ber of under-five-year group was 180 (74%). Out of a
total of 236 patients, 221 (93.6%) with a median age
of 21 months (1–168 months) were scar positive and
15 (6.4%) cases with a median age of 42 months (1–
48 S. Sayyahfar et al.156 months) did not have a scar. However, scar neg-
ative rate in children under and above 60 months
was 5.7% and 8.3%, respectively, which was not sta-
tistically significant (p-value = 0.54). The character-
istics of these two groups are shown in Table 2.
Comparison of the response to human PPD in scar po-
sitive and negative groups (not considering indeter-
minate results) is shown in Table 3. All TST positive
cases were IGRA positive. There was no statistically
significant distinction between results of TST and
IGRA in scar positive and negative groups. Mean dif-
ference between two study groups evaluated by
both t-independent test and non-parametric
Mann–Whitney test was not significant (p-values
0.15 and 0.14 respectively).
The agreement between TST and IGRA results
was poor (actual agreement = 43.5%, Kap-
pa = 0.004, p-value = 0.87).
4. Discussion
Currently, BCG vaccine is injected at birth to
nearly all newborns in Iran under the expanded pro-
gram of immunization, but does not always result
in scar formation.
A sequence of changes develops that result in a
BCG vaccine scar. Two to three weeks after an
appropriately administered injection of a potent
dose of BCG vaccine, a papule develops at the site
of injection which slowly increases in size, and at
5 weeks reaches between 4 and 8 mm. Then it
ulcerates and within 6–12 weeks heals spontane-
ously and leaves a permanent scar [6].
The onset and completion of scar formation
occurs after 12 weeks in 47.2–100% of BCG vacci-
nated newborns, but can be delayed for six months
or longer [2,6–12]. In this study 6.4% of cases were
scar negative. The rate of scar failure in other
studies was wide and ranged from 5% to 16% whenTable 2 The characteristics of scar negative and positive gro
Characteristic Scar ne
Number 15 (6.4
Age (months)
Median 4
Range 1–156
<5 years 10 (67%
Male 9 (60%)
TST
Negative 15 (100
Positive 0%
Human PPD based IGRA
Indeterminate 1 (6.6%
Positive 10 (66.
Negative 4 (26.7the BCG vaccine was administered at birth [2,11–
14].
There is a difference between scar failure and
abortive reaction. Scar failure means that scar for-
mation does not occur after BCG vaccination,
which happens in about 10% of vaccinated cases;
but abortive reaction means that the BCG scar
may disappear after the passage of time [6]. In a
prospective study, abortive reactions occurred in
9.9% of infants [15]. Different reasons such as weak
vaccine, lost potency and wrong technique are con-
sidered responsible for scar failure [12].
This study was cross-sectional, so it could not
differentiate between these two groups. Scar fail-
ure causes clinical concern in some physicians
who believe that the absence of scar formation at
the site of inoculation may be indicative of unsuc-
cessful BCG vaccination in an individual and some
recommend performing TST for such cases and if
negative consider revaccination [16,17].
From 2001 IGRA has been used as an aid for
detecting MTB infection. The test is based on
the measurement of IFN-c released from sensi-
tized lymphocytes exposed with Mycobacterium
antigen. IFN-c is a cytokine mainly released by
T-lymphocytes after antigenic stimulation. It plays
a major role in immune responsiveness to M.
tuberculosis as the major macrophage activating
factor [18].
Many commercial and research versions of IGRA
that use different types of Mycobacterium antigens
are available; some are based on MTB specific anti-
gens, such as early secreted antigenic target 6
(ESAT-6) and culture filtrate protein 10 (CFP10),
but the human PPD-based IGRA was chosen so that
the antigens used to compare responsiveness were
similar to those present in the TST [19].
In this study 71.4% of scar negative-TST negative
cases had positive human PPD-based IGRA results.ups.
gative Scar positive
%) 221 (93.6%)
21
1–168
) 166 (75%)
124 (56%)
%) 210 (95%)
11 (5%)
) 26 (11.7 %)
7%) 110 (49.8%)
%) 85 (38.5%)
Table 3 Comparison of interferon gamma response to human PPD, in scar positive and negative groups (not considering
indeterminate results).
Scar positive Scar negative p-Value
Human PPD based IGRA 110 (56.4%) 10 (71.4%) 0.27
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to human PPD antigens might exist.
Surprisingly, the number of scar negative-IGRA
positive cases was more than scar positive-IGRA po-
sitive cases and this may be contrary to the results
of a study performed by Anuradha et al. [20]. Host
genetic factors of the vaccinated children such as
polymorphism in IFN-c (_874T/A) gene may play
an important role in IFN-c response to mycobacte-
rium antigens. Children with TT genotype produce
higher levels of IFN-c compared with the other
genotypes AT and AA [20]. A genetic study to deter-
mine A and T alleles in scar positive and negative
groups was not performed. In addition, the differ-
ence in numbers between these two groups might
have some influence on the results.
In this study the indeterminate result of IGRA in
the scar negative and positive groups was 6.6% and
11.7% respectively. In adult studies, indeterminate
results were 0.1–11% in different studies and in
one of the recent studies, 21.4% of cases had inde-
terminate results [21,22]. In one pediatric study,
Connell et al. reported 17% indeterminate results
[21]. Indeterminate result means that the positive
control (mitogen) fails to react. This may be owing
to several factors, such as lymphocytopenia, very
young or very old age, congenital or acquired im-
mune deficiencies and usage of steroid or other im-
mune suppressant agents, or lymphocyte damage
following freezing of the blood sample during
transport [23]. The reason for this problem in this
study is not very obvious because none of the par-
ticipants were immune-deficient, and there was no
error in transport, handling and processing, which
may destroy the lymphocytes in the blood samples.
In pediatric studies indeterminate results are more
than adults, so the indeterminate results of this
study might be a result of the age of cases [21].
In this study the agreement between TST and
IGRA results was poor (actual agreement = 43.5%,
kappa = 0.004, p-value = 0.87). Kang et al. also
found a poor correlation between TST and IGRA
among healthy volunteers [24]. It seems that con-
cordance between TST and IGRA is related to
studied population characteristics, including BCG
vaccination status, risk of exposure to MTB and
also the type of antigens used for IGRA. The stud-
ied cases had a low risk of exposure to MTB be-cause one of our most important exclusion
criteria was any history of active TB disease or
close contact with a patient with TB disease. In
addition, all of them were administered the BCG
vaccine at birth and there might be some cross-
reaction between human PPD as the main Ag used
in human PPD-based IGRA and the BCG vaccine.
These reasons might explain the discrepancy
found between TST and IGRA results in the study
cases. In contrary, Okada et al. and Tsiouris
et al. found agreement between these two tests
(Kappa = 0.63 and 0.56, respectively) [25,26]. In
both studies the participants were at a high risk
for MTB Infection, and the aim of IGRA usage
was the evaluation of MTB infection in their stud-
ied population. In addition, antigen-specific based
IGRA was used that contained antigens, such as
ESAT6 and CFP10, which had no cross-reaction
with BCG vaccine antigens that might influence
the agreement.
The CDC recommends that when the probability
of latent TB infection (LTBI) is low, treatment is
not suggested for persons at a low risk who are
IGRA positive but TST negative. In addition, the
CDC discourages the use of diagnostic tests for LTBI
among populations at a low risk for infection with
MTB because of the high rates of false positive re-
sults. Also, positive human PPD-based IGRA results
in BCG vaccinated children may relate to a cross-
reaction between BCG vaccine antigens and human
PPD rather than infection with MTB, therefore, it is
believed that these cases did not need treatment
and/or follow-up [27].
The study had some limitations:
(1) The number of scar negative cases was few, so it is
suggested to repeat this investigation with more
cases.
(2) The number of abortive reaction cases could not be
determined, so it is suggested that an investigation
comparing the gamma interferon response
between cases with scar failure and those in whom
the scar fades with time be designed.
5. Conclusion
To conclude, it seems that immune responsiveness
to human PPD in scar negative and positive children
50 S. Sayyahfar et al.may not correspond to TST results, and scar nega-
tive children may be better evaluated with a more
accurate tool, such as IGRA than contenting with
TST alone. In addition, apparent discordance be-
tween TST and IGRA that results in scar negative
cases would argue against the practice of using
TST in scar negative children.
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